Hospital
Saint Francis Hospital Muskogee INC
Saint Francis Hospital Muskogee INC was paid $16.79M by Medicaid between Jan 2018 and Dec 2024, across 94 billing codes. Its largest line is 99284, emergency room visit (serious) — 28% of everything it billed.
33Billing provider infoSAINT FRANCIS HOSPITAL MUSKOGEE INC
MUSKOGEE, OK 74401
MUSKOGEE, OK 74401
33aNPI1386188837assigned 12/16/2016
33bProvider typeGeneral Acute Care Hospital
28Total paid$16.79M
24GClaims197,482
24DCodes billed94
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in Oklahoma
Rank by total paid#8 of 75
Median peer was paid$3.66M
This provider vs. median4.6×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 18,547 | $1.40M | |
| 2019 | 23,514 | $2.18M | |
| 2020 | 17,047 | $1.58M | |
| 2021 | 23,548 | $1.81M | |
| 2022 | 43,547 | $3.38M | |
| 2023 | 47,567 | $4.27M | |
| 2024incomplete | 23,712 | $2.17M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 28% | 20,178 | 19,985 | $4.77M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 18% | 9,052 | 8,989 | $2.99M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 14% | 14,779 | 14,671 | $2.37M |
| 42820 | Tonsillectomy and adenoidectomy; younger than age 12 | 8.5% | 398 | 398 | $1.42M |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 5.2% | 7,280 | 7,188 | $870K |
| 69436 | Tympanostomy (requiring insertion of ventilating tube), general anesthesia | 4.0% | 936 | 935 | $678K |
| 87631 | 2.9% | 3,923 | 3,915 | $495K | |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | 2.8% | 2,731 | 1,726 | $466K |
| 96375 | Therapeutic injection; each additional sequential IV push | 2.0% | 7,723 | 6,538 | $342K |
| D9999 | Unspecified adjunctive procedure, by report | 1.7% | 342 | 342 | $291K |
| 80053 | Comprehensive metabolic panel | 1.6% | 21,296 | 20,260 | $261K |
| 96361 | Intravenous infusion, hydration; each additional hour | 1.5% | 5,188 | 5,013 | $251K |
82 more codes
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 24,222 | $163K |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 423 | $157K |
| J0897 | Injection, denosumab, 1 mg | <1% | 124 | $149K |
| 71045 | Radiologic examination, chest; single view | <1% | 9,616 | $113K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | <1% | 581 | $96K |
| 93010 | Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | <1% | 12,501 | $83K |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | <1% | 351 | $70K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | <1% | 731 | $55K |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 1,153 | $52K |
| 99291 | Critical care, evaluation and management of the critically ill patient, first 30-74 minutes | <1% | 117 | $51K |
| 78815 | Positron emission tomography (PET) for limited area imaging | <1% | 65 | $48K |
| 99214 | Doctor's office visit, returning patient (more involved) | <1% | 739 | $48K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 385 | $44K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 618 | $43K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 774 | $41K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 6,774 | $40K |
| 81001 | <1% | 10,375 | $32K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 5,990 | $26K |
| 84703 | <1% | 4,031 | $25K | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 975 | $22K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 271 | $21K |
| 42830 | <1% | 12 | $20K | |
| 84484 | <1% | 1,770 | $19K | |
| 96523 | <1% | 365 | $19K | |
| 83690 | <1% | 2,565 | $15K | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 618 | $14K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 189 | $14K |
| 43249 | <1% | 12 | $12K | |
| 83735 | <1% | 1,923 | $11K | |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 184 | $9K |
| 83605 | <1% | 888 | $9K | |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 150 | $9K |
| 88300 | <1% | 403 | $8K | |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 82 | $7K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 112 | $5K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 62 | $4K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 772 | $4K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 72 | $4K |
| 96417 | <1% | 57 | $3K | |
| 71046 | Radiologic examination, chest; 2 views | <1% | 161 | $3K |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 66 | $2K |
| 81025 | <1% | 323 | $2K | |
| 73721 | Magnetic resonance imaging, any joint of lower extremity; without contrast material | <1% | 15 | $2K |
| 83880 | <1% | 42 | $1K | |
| 87807 | <1% | 108 | $1K | |
| 87077 | <1% | 202 | $1K | |
| 85027 | <1% | 192 | $1K | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 1,065 | $993.81 |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 68 | $972.60 |
| 96401 | <1% | 26 | $792.72 | |
| J2469 | Injection, palonosetron hcl, 25 mcg | <1% | 80 | $754.00 |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 51 | $720.30 |
| 82728 | <1% | 58 | $657.54 | |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 14 | $625.80 |
| 84466 | <1% | 58 | $615.78 | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 1,593 | $589.33 |
| 86780 | <1% | 50 | $589.00 | |
| 86850 | <1% | 71 | $543.27 | |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 17 | $530.57 |
| 87486 | <1% | 17 | $530.57 | |
| 87581 | <1% | 17 | $530.57 | |
| 85007 | <1% | 159 | $507.40 | |
| 81003 | <1% | 211 | $456.27 | |
| 87070 | <1% | 56 | $427.11 | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 28 | $349.01 |
| 83540 | <1% | 58 | $311.95 | |
| 94060 | <1% | 13 | $270.07 | |
| 73630 | <1% | 14 | $264.13 | |
| 87081 | <1% | 33 | $222.09 | |
| 86900 | <1% | 84 | $198.87 | |
| 94761 | <1% | 6,237 | $185.22 | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 25 | $172.32 |
| 86901 | <1% | 71 | $161.85 | |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 27 | $154.38 |
| 82950 | <1% | 12 | $46.53 | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 149 | $4.45 |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | 0% | 298 | $0.00 |
| J7030 | Infusion, normal saline solution , 1000 cc | 0% | 73 | $0.00 |
| J7120 | Ringers lactate infusion, up to 1000 cc | 0% | 41 | $0.00 |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | 0% | 569 | $0.00 |
| C1889 | Implantable/insertable device, not otherwise classified | 0% | 134 | $0.00 |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | 0% | 18 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialSMITH, BARRY (SYSTEM DIRECTOR, REV CYCLE SUPPORT)
| Provider | Location | Paid |
|---|---|---|
| Saint Francis Outreach Services LLC | Tulsa, OK | $15.74M |
| Saint Francis Hospital South LLC | Tulsa, OK | $11.12M |
| Saint Francis Hospital Vinita, INC | Vinita, OK | $6.44M |
| Laureate Psychiatric Clinic and Hospital INC | Tulsa, OK | $729K |
| Saint Francis Hospital South LLC | Tulsa, OK | $51K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.